142 related articles for article (PubMed ID: 36943383)
1. Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Wang X; Li M; Zeng X; Wang Q
Rheumatology (Oxford); 2023 Oct; 62(10):e293-e294. PubMed ID: 36943383
[No Abstract] [Full Text] [Related]
2. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Wu EY; Schanberg LE; Wershba EC; Rabinovich CE
Lupus; 2017 May; 26(6):646-649. PubMed ID: 27837194
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Yuki EFN; Silva CA; Aikawa NE; Romiti R; Heise CO; Bonfa E; Pasoto SG
J Clin Rheumatol; 2021 Sep; 27(6):248-259. PubMed ID: 31693649
[TBL] [Abstract][Full Text] [Related]
4. Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
Sherman MA; Srinivasalu H; Kirkorian AY; Cardis MA
Arthritis Rheumatol; 2023 Jan; 75(1):120. PubMed ID: 35997717
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Braunstein I; Goodman NG; Rosenbach M; Okawa J; Shah A; Krathen M; Kovarik CL; Luning Prak E; Werth VP
J Am Acad Dermatol; 2012 Apr; 66(4):571-82. PubMed ID: 21821308
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.
Wang D; Chen H; Wang S; Zou Y; Li J; Pan J; Wang X; Ren T; Zhang Y; Chen Z; Feng X; Sun L
Clin Rheumatol; 2016 Jun; 35(6):1521-7. PubMed ID: 27097914
[TBL] [Abstract][Full Text] [Related]
8. [Thalidomide therapy of cutaneous lupus erythematosus].
Bohmeyer J; Achenbach A; Westenberger M; Stadler R
Hautarzt; 2002 Nov; 53(11):744-8. PubMed ID: 12402138
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
Okon L; Rosenbach M; Krathen M; Rose M; Propert K; Okawa J; Werth V
J Am Acad Dermatol; 2014 Mar; 70(3):583-4. PubMed ID: 24528907
[No Abstract] [Full Text] [Related]
11. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
Fennira F; Chasset F; Soubrier M; Cordel N; Petit A; Francès C
J Am Acad Dermatol; 2016 Jun; 74(6):1248-51. PubMed ID: 27185425
[No Abstract] [Full Text] [Related]
12. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide.
Atra E; Sato EI
Clin Exp Rheumatol; 1993; 11(5):487-93. PubMed ID: 8275583
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of lenalidomide in refractory lupus pernio.
Dalm VA; van Hagen PM
JAMA Dermatol; 2013 Apr; 149(4):493-4. PubMed ID: 23715134
[No Abstract] [Full Text] [Related]
14. [Refractory subacute cutaneous lupus erythematosus treated with rituximab].
Cieza-Díaz DE; Avilés-Izquierdo JA; Ceballos-Rodríguez C; Suárez-Fernández R
Actas Dermosifiliogr; 2012; 103(6):555-7. PubMed ID: 22482740
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
Reymann V; Bessis D; Bergeret B; Lipsker D; Du-Thanh A; Terrail N; Dandurand M; Dereure O
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):e113-e115. PubMed ID: 32730681
[No Abstract] [Full Text] [Related]
16. One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels.
Yuki EFN; Soares R; Kupa LVK; Heise CO; Aikawa NE; Arnone M; Romiti R; Pedrosa TDN; Silva CAAD; Bonfa E; Pasoto SG
Lupus; 2021 May; 30(6):956-964. PubMed ID: 33657919
[TBL] [Abstract][Full Text] [Related]
17. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus.
Housman TS; Jorizzo JL; McCarty MA; Grummer SE; Fleischer AB; Sutej PG
Arch Dermatol; 2003 Jan; 139(1):50-4. PubMed ID: 12533164
[TBL] [Abstract][Full Text] [Related]
18. [Thalidomide and thrombosis].
Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L
Ann Dermatol Venereol; 2000 Feb; 127(2):171-4. PubMed ID: 10739975
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus.
Walchner M; Meurer M; Plewig G; Messer G
Int J Dermatol; 2000 May; 39(5):383-8. PubMed ID: 10849134
[TBL] [Abstract][Full Text] [Related]
20. Oral manifestations of patients with lupus erythematosus.
Brennan MT; Valerin MA; Napeñas JJ; Lockhart PB
Dent Clin North Am; 2005 Jan; 49(1):127-41, ix. PubMed ID: 15567365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
